CELGENE CORPORATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2007-01-11

Last Posted Date: 2012-05-21

Lead Sponsor: Celgene Corporation

Target Recruit Count: 587

Registration Number: NCT00420849

Locations: 🇦🇹
Wilhelminenspital, Vienna, Montlearstrasse 37, Austria
🇮🇪
St James's Hospital, Dublin, Ireland
🇪🇸
H. Clínico de Salamanca, Salamanca, Spain

and more 2 locations

A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia
Leukemia, B-Cell, Chronic

Interventions: Drug: lenalidomide

First Posted Date: 2007-01-08

Last Posted Date: 2019-11-08

Lead Sponsor: Celgene

Target Recruit Count: 52

Registration Number: NCT00419250

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
Indiana University Medical center, Indianapolis, Indiana, United States
🇺🇸
The Cleveland Clinic Foundation, Cleveland, Ohio, United States

and more 32 locations

A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma, Non-Hodgkin's

Interventions: Drug: lenalidomide

First Posted Date: 2006-12-19

Last Posted Date: 2017-03-01

Lead Sponsor: Celgene

Target Recruit Count: 217

Registration Number: NCT00413036

Locations: 🇺🇸
Ochsner Clinic Foundation, Baton Rouge, Louisiana, United States
🇺🇸
Palm Beach Cancer Institute, West Palm Beach, Florida, United States
🇺🇸
Access Clinical Research, Rancho Mirage, California, United States

and more 45 locations

ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma

Phase 1

Terminated

Conditions: Ovarian Neoplasms
Fallopian Tube Neoplasms
Peritoneal Neoplasms

First Posted Date: 2006-12-05

Last Posted Date: 2019-10-18

Lead Sponsor: Celgene

Target Recruit Count: 6

Registration Number: NCT00407407

Locations: 🇺🇸
University of Texas, MD Anderson Cancer Center, Houston, Texas, United States

A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.

Phase 3

Completed

Conditions: Newly Diagnosed Multiple Myeloma

Interventions: Drug: Melphalan
Drug: Prednisone
Drug: Aspirin
Drug: Placebo

First Posted Date: 2006-11-30

Last Posted Date: 2017-01-11

Lead Sponsor: Celgene Corporation

Target Recruit Count: 459

Registration Number: NCT00405756

Locations: 🇦🇹
University Hospital Innsbruck, Innsbruck, Austria
🇧🇾
Republican Scientific and Practical Centre of Radiation Medicine and Human Ecology, Gomel, Belarus
🇧🇪
AZ St-Jan Brugge Oostende AV, Brugge, Belgium

and more 94 locations

Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer

Phase 1

Completed

Conditions: Metastatic Pancreatic Cancer

Interventions: Drug: Gemcitabine
Drug: Albumin-bound paclitaxel

First Posted Date: 2006-11-10

Last Posted Date: 2019-11-22

Lead Sponsor: Celgene

Target Recruit Count: 67

Registration Number: NCT00398086

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Scottsdale Healthcare/Virginia Pipe Cancer Institute, Scottsdale, Arizona, United States
🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Ctr, Birmingham, Alabama, United States

and more 2 locations

Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma

Phase 1

Completed

Conditions: Lymphomas
Cancer

Interventions: Drug: NPI-0052

First Posted Date: 2006-11-08

Last Posted Date: 2017-11-22

Lead Sponsor: Celgene

Target Recruit Count: 51

Registration Number: NCT00396864

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
Univ. of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Premiere Oncology of America, Scottsdale, Arizona, United States

Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Adriamycin and Cytoxan (AC)
Drug: ABI-007
Drug: Taxol
Drug: Bevacizumab
Drug: pegfilgrastim

First Posted Date: 2006-10-31

Last Posted Date: 2019-11-25

Lead Sponsor: Celgene

Target Recruit Count: 197

Registration Number: NCT00394251

ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: ABI-007
Drug: Bevacizumab

First Posted Date: 2006-10-31

Last Posted Date: 2019-11-25

Lead Sponsor: Celgene

Target Recruit Count: 50

Registration Number: NCT00394082

Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Small Cell Lung Cancer

Interventions: Drug: Amrubicin
Drug: Cisplatin
Drug: Etoposide

First Posted Date: 2006-10-17

Last Posted Date: 2019-11-19

Lead Sponsor: Celgene

Target Recruit Count: 99

Registration Number: NCT00388960

Locations: 🇳🇱
Academisch Medisch Centrum, Amsterdam, Netherlands
🇳🇱
Medisch Spectrum Twente - Dept of Pulmonary Diseases, Enschede, Netherlands
🇳🇱
Academisch Ziekenhuis Maastricht, Maastricht, Netherlands

and more 22 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy